ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年07月31日 08時00分
Source:
Eisai
エーザイ、E2082の臨床第I相試験(治験)における死亡例の発生について
東京, 2019年07月31日 - (JCN Newswire) - 当社が日本国内で実施していた健康成人を対象とした臨床第I相試験(治験)において、2019 年6 月に、1 名の被験者様が治験薬の投与を完了後にお亡くなりになりました。被験者様のご冥福をお祈り申し上げると共に、ご遺族様には謹んでお悔やみ申し上げます。
今回の治験で用いた治験薬は、神経系に作用する薬剤として当社が開発を進めておりました E2082です。
治験薬と被験者様の死亡の因果関係は不明であり、また、これまでに本治験において他の被験者様に重篤な副作用は報告されておりません。なお、E2082 の治験での投与は既にすべて中止しております。
当社は、速やかに厚生労働省に本事案を報告の上、同省の調査に積極的に協力しております。
当社は、被験者様がお亡くなりになったことを極めて重く受け止め、引き続き安全性に十分配慮し、高い倫理観を持って、医薬品の研究開発を行ってまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/pdf/news201958pdf.pdf
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
NEC Security to Provide Cybersecurity Services for GREENxEXPO 2027 (International Horticultural Expo 2027,Yokohama, Japan)
Oct 03, 2025 23:01 JST
Honda Announces New Investment in Motorcycle Plant in Brazil
Oct 03, 2025 22:36 JST
Mitsubishi Heavy Industries Thermal Systems Has Launched "ETI-W"
Oct 03, 2025 22:15 JST
Fujitsu expands strategic collaboration with NVIDIA to deliver full-stack AI infrastructure
Oct 03, 2025 21:24 JST
MHI Starts a Study on Optimizing the Decarbonization Value Chain Using Green Hydrogen and Ammonia Exported from India
Oct 03, 2025 18:34 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
Oct 03, 2025 18:01 JST
Mazda Ranked Highest in J.D. Power 2025 Japan Sales Satisfaction Index Study for Second Consecutive Year in Mass Market Domestic Brands Segment
Oct 03, 2025 17:38 JST
MHI and QST Complete the First Outer Vertical Target of the Divertor for the ITER Project in Southern France
Oct 03, 2025 16:57 JST
MHI Signs Memorandum of Agreement with University of the Philippines to Consider Decarbonization Strategies in the Philippines
Oct 03, 2025 16:30 JST
Sharp and ESI Asia Pacific partner to pioneer zinc-air flow battery technology in Queensland, Australia
Oct 03, 2025 07:30 JST
JCB launches strategic guide for European merchants looking to tap into Asian travellers' spending power
Oct 02, 2025 12:00 JST
Fujitsu showcases AI technologies for human augmentation at CEATEC 2025
Oct 01, 2025 23:09 JST
DOCOMO and PaMeLa Develop World's First Technology to Share Pain Perception Tailored to Individual Sensitivity
Oct 01, 2025 22:18 JST
Strategic Partnership and Investment with Eagers Automotive Ltd., Including Investment in Unique Independent Used Car Business Across Australia and New Zealand
Oct 01, 2025 21:26 JST
The Second Proton Therapy System Begins Treatment at University of Tsukuba Hospital
Oct 01, 2025 20:37 JST
Hitachi Energy invests an additional $270 million CAD ($195 million USD) to expand large power transformer manufacturing capacity in Varennes, Quebec
Oct 01, 2025 19:33 JST
JCB Launches Exclusive Giant Gacha Experience in Shibuya
Oct 01, 2025 12:00 JST
Olympus Launches OLYSENSE CAD/AI in the US and Europe
Sep 30, 2025 22:00 JST
Ouribank Signs Agreement with NEC to Implement AI-Native Data Center and Campus Network from HPE Juniper Networking for Enhanced Operational Efficiency
Sep 30, 2025 19:52 JST
Toyota Launches Strategic Investment Subsidiary and Woven Capital Fund II to Accelerate Transformation into a Mobility Company
Sep 30, 2025 19:34 JST
More Latest Release >>
Related Release
Eisai Highlights Breadth of Oncology Research at ESMO 2025
10/3/2025 6:01:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
9/29/2025 10:33:00 AM JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
9/24/2025 7:04:00 PM JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
9/17/2025 6:20:00 PM JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
9/12/2025 1:20:00 PM JST
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
9/8/2025 5:49:00 PM JST
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
9/4/2025 10:56:00 AM JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
9/3/2025 11:32:00 AM JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
9/1/2025 1:44:00 PM JST
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
8/29/2025 6:17:00 PM JST
More Press release >>